Advertisement
Screener

Neuphoria Therapeutics Inc. (NEUP) Form 6-K: Report of foreign private issuer

1.1 / 5 stars · 5/22 Roast Me

Add as a preferred source on Google

Neuphoria Therapeutics Inc. Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2024-06-03: Form 6-K; Period of report 2024-06-03; Description 6-K; Document bnox_6k_spa.htm.
  • 2024-03-15: Form 6-K; Period of report 2024-03-15; Description 6-K; Document bionomics_-_6k_hye_2024.htm.
  • 2024-01-04: Form 6-K; Period of report 2024-01-04; Description 6-K; Document bnox-6k-ceoacquiresshare.htm.
  • 2023-11-30: Form 6-K; Period of report 2023-11-30; Description 6-K; Document bnox-6k-2023agm_results.htm.
FiledFormPeriod of reportDescriptionDocument
2024-06-036-K2024-06-036-Kbnox_6k_spa.htm
2024-03-156-K2024-03-156-Kbionomics_-_6k_hye_2024.htm
2024-01-046-K2024-01-046-Kbnox-6k-ceoacquiresshare.htm
2023-11-306-K2023-11-306-Kbnox-6k-2023agm_results.htm
2023-11-286-K2023-11-286-Kbnox-6k-dirresignation.htm
2023-11-036-K2023-11-036-Kbnox-6k-noticeof2023agm.htm
2023-10-166-K2023-10-166-Kbnox-6k-endofph2meetingw.htm
2023-09-296-K2023-09-296-Kbnox-_stat_report-2023.htm
2023-09-286-K2023-09-286-Kbnox-6k-attune_ph2b_tria.htm
2023-07-316-K2023-07-316-Kbnox-6k-app4c_q4_2023a.htm
2023-07-286-K2023-07-286-Kbnox-6k-asxshareholderle.htm
2023-07-256-K2023-07-256-Kbnox-6k-delistfromasx.htm
2023-07-246-K2023-07-246-Kbnox-6k-tradinghaltasx.htm
2023-07-076-K2023-07-076-Kbnox-6k-kmpoptionexpiry.htm
2023-07-076-K2023-04-286-Kbnox-6k-app4c_q3_2023_2.htm
2023-07-036-K2023-07-036-Kbnox-6k-keyleadershipupd.htm
2023-04-276-K2023-04-276-Kbnox-6k-attune_update.htm
2023-03-096-K2023-03-096-Kbnox-6k-prevail_update.htm
2023-02-236-K2023-02-236-Kbnox-6k-changedirint_eds.htm
2023-02-236-K2023-02-236-Kbionomics_-_6k_hye_2023_.htm
2023-02-216-K2023-02-216-Kbnox-6k-egm_results.htm
2023-01-306-K2023-01-306-Kbnox-6k-app4c_q2_2023.htm
2023-01-186-K2023-01-186-Kbnox-6k-noticeofegm.htm
2023-01-096-K2023-01-096-Kbnox-6k-directorintoptio.htm
2022-12-196-K2022-12-196-Kbnox-6k-prevail_results.htm
2022-12-166-K2022-12-166-Kbnox-6k-appoint_ceo.htm
2022-11-166-K2022-11-166-Kbnox-6k-agm_results.htm
2022-10-256-K2022-10-256-Kbnox-6k-app4c_q1_2023.htm
2022-10-186-K2022-10-186-Kbnox-6k-rdtaxrefundfy22.htm
2022-10-186-K2022-10-186-Kbnox-6k-noticeofagm.htm
2022-10-066-K2022-10-066-Kbnox_2022_annual_report_.htm
2022-10-046-K2022-10-046-Kbnox-6k-cantorconf.htm
2022-09-216-K2022-09-216-Kbnox-6k-hostkolwebinar.htm
2022-08-256-K2022-08-256-Kbnox-_app4e__stat_report.htm
2022-08-086-K2022-08-086-Kbnox-6k-rdtaxincentivere.htm
2022-07-296-K2022-07-296-Kbnox-6k-app4c_q4_2022.htm
2022-07-206-K2022-07-206-Kbnox-6k-issue_of_options.htm
2022-07-056-K2022-07-056-Kbnox-6k-expiryunlistedop.htm
2022-06-136-K2022-06-136-Kbnox-6k-investorwebinarj.htm
2022-05-186-K2022-05-186-Kbnox-6k-changedirint_md.htm
2022-05-166-K2022-05-166-Kbnox-6k-investorconferen.htm
2022-04-296-K2022-04-296-Kbnox-6k-app4c_q3_2022.htm
2022-02-236-K2022-01-316-Kbionomics_-_6k_hye_-_app.htm
2022-01-286-K2022-01-286-Kbnox-6k-app4c-280122.htm
2022-01-126-K2022-01-126-Kd248808d6k.htm
2022-01-046-K2022-01-046-Kd112589d6k.htm
2022-01-036-K2022-01-036-Kd39249d6k.htm
2021-12-226-K2021-12-226-Kd277473d6k.htm

Similar stocks

Stock NameCountryMarket CapPE Ratio
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
Advertisement